09:01 AM EDT, 09/26/2024 (MT Newswires) -- Emergent Biosolutions ( EBS ) said Thursday that it has been awarded two contract options worth $67.4 million by the US government to obtain additional treatment courses of Tembexa to support smallpox preparedness.

The options are part of Emergent's existing 10-year contract, which has a maximum potential value of $568 million.

Price: 6.00, Change: +0.06, Percent Change: +1.01